GlassScriptPhysician profile
Stacey Mcgrady
NPI 1316670920
$8,397.37
in general payments reported to CMS, 2019-2025
41 companies · $2,895 in 2025
The $2,895 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $657 · 2023: $2,278 · 2024: $2,567 · 2025: $2,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,481 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,481.25 |
| Education | $258.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,465.36 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,300.21 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Lilly USA, LLC | $493.51 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $486.61 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $465.70 | 2022-2025 | Imfinzi, Lynparza, Enhertu |
| Incyte Corporation | $351.66 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Pharmaessentia USA Corporation | $330.44 | 2023-2025 | Besremi |
| Celgene Corporation | $313.25 | 2022-2025 | Reblozyl |
| Pfizer INC. | $308.94 | 2023-2025 | |
| Astellas Pharma US INC | $296.98 | 2023-2025 | Xtandi, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $281.59 | 2023-2025 | |
| Seagen INC. | $243.61 | 2022-2025 | Adcetris |
| Genzyme Corporation | $177.78 | 2022-2025 | |
| Coherus Oncology, INC. | $175.20 | 2024-2025 | Loqtorzi |
| Sobi, INC | $155.48 | 2022-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $131.84 | 2023-2025 | Venclexta, Polivy, Columvi |
| Puma Biotechnology, INC. | $120.03 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $106.83 | 2022-2024 | Soliris, Ultomiris |
| Glaxosmithkline, LLC. | $103.24 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Aveo Pharmaceuticals, INC. | $94.20 | 2022-2025 | Fotivda |
| Exelixis INC. | $86.42 | 2024-2025 | Cabometyx |
| Myriad Genetic Laboratories, INC. | $85.74 | 2023-2024 | Bracanalysis Cdx, Myrisk |
| Daiichi Sankyo INC. | $83.56 | 2022-2025 | Datroway, Enhertu |
| Stemline Therapeutics INC. | $62.52 | 2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $62.43 | 2025 | Libtayo |
| Sumitomo Pharma America, INC. | $61.97 | 2024 | Orgovyx |
| Beone Medicines USA, INC. | $60.50 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $59.22 | 2022-2025 | Darzalex, Talvey, Rybrevant |
| Karyopharm Therapeutics INC. | $56.88 | 2022-2025 | Xpovio |
| Kite Pharma, INC. | $53.21 | 2023-2024 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $46.54 | 2023 | Imbruvica |
| Immunogen, INC. | $45.89 | 2023-2024 | Elahere, Elahere |
| Abbvie INC. | $42.11 | 2025 | |
| Global Blood Therapeutics, INC. | $32.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.70 | 2025 | Fruzaqla |
| Merck Sharp & Dohme LLC | $31.93 | 2024 | Keytruda |
| Sun Pharmaceutical Industries INC. | $21.68 | 2025 | |
| Taiho Oncology, INC. | $18.86 | 2023 | |
| Myovant Sciences INC. | $16.95 | 2022 | |
| Morphosys, US INC. | $16.81 | 2022 | |
| Apellis Pharmaceuticals, INC. | $16.09 | 2023 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Mcgrady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.